Find your next paid study

Acerand Therapeutics (Hong Kong) LimitedNCT06801236

~$150 – $4,200

Actual pay is set by the research site.

Advanced Metastatic Castration-resistant Prostate CancerProstate Specific Membrane Antigen (PSMA) Expression

A Phase 1 Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of 225Ac-PSMA-Trillium in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC). mCRPC is a cancer of the pros…

~$150 – $4,500

Actual pay is set by the research site.

BayerNCT06217822

A Phase 2a Study of High Dose Testosterone Followed by Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer

The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic cast…

H. Lee Moffitt Cancer Center and Research InstituteNCT07476001

~$75 – $2,000

Actual pay is set by the research site.

A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who…

Syntrix Biosystems, Inc.NCT06228053

~$75 – $2,800

Actual pay is set by the research site.

Prostate CancerMetastatic Castration-resistant Prostate CancermCRPC+3 more

An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer

To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostat…

Blue Earth Therapeutics LtdNCT05413850

~$150 – $4,200

Actual pay is set by the research site.

Metastatic Castration-Resistant Prostate Cancer

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen re…

Hoffmann-La RocheNCT07287150

~$75 – $3,000

Actual pay is set by the research site.

Metastatic Castration-resistant Prostate Cancer (mCRPC)

A Phase 1b, Open-label Study of Xaluritamig (AMG 509) in Adults With Metastatic Castration-resistant Prostate Cancer

The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-…

~$150 – $4,500

Actual pay is set by the research site.

AmgenNCT07493512

PRO-XL: A Phase II Study of XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer After Progression on Lutetium-177 (177Lu)-PSMA-617

The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers wil…

University of UtahNCT06568562

~$75 – $2,000

Actual pay is set by the research site.

Metastatic Castration-resistant Prostate Cancer (mCRPC)

A Phase I/II Study to Determine the Safety and Efficacy of a Combination of Green Tea and Quercetin With Docetaxel in Castration-resistant Prostate Cancer Patients

The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of adv…

Charles Drew University of Medicine and ScienceNCT06615752

~$150 – $3,000

Actual pay is set by the research site.

Metastatic Castration-Resistant Prostate CancerProstate Cancer Patients With Bone MetastasisProstate Cancer (CRPC)+2 more

177Lu-PSMA-617 (Pluvicto) for the Treatment of Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Super Scan Bone Scan

The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prost…

Ebrahim S DelpassandNCT06972628

~$75 – $3,000

Actual pay is set by the research site.

Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8+4 more

Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy

This phase I/II trial tests the safety, side effects, and best dose of abemaciclib and whether it works before 177Lu-PSMA-617 in treating patients with castrat…

~$150 – $4,500

Actual pay is set by the research site.

Vadim S Koshkin

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response Via Modulation of ANdrogen Receptor (the SPIDERMAN Trial)

The objective of this study is to determine the safety and clinical effects of alternating pharmacologic (i.e. supraphysiologic) testosterone therapy with daro…